Background-Heart failure is the leading cause of death in the United States. By delineating the pathways that regulate cardiomyocyte function, we can better understand the pathogenesis of cardiac disease. Many cardiomyocyte signaling pathways activate protein tyrosine kinases. However, the role of specific protein tyrosine phosphatases (PTPs) in these pathways is unknown. Methods and Results-Here, we show that mice with muscle-specific deletion of Ptpn11, the gene encoding the SH2 domain-containing PTP Shp2, rapidly develop a compensated dilated cardiomyopathy without an intervening hypertrophic phase, with signs of cardiac dysfunction appearing by the second postnatal month. Shp2-deficient primary cardiomyocytes are defective in extracellular signal-regulated kinase/mitogen-activated protein kinase (Erk/MAPK) activation in response to a variety of soluble agonists and pressure overload but show hyperactivation of the RhoA signaling pathway. Treatment of primary cardiomyocytes with Erk1/2-and RhoA pathway-specific inhibitors suggests that both abnormal Erk/MAPK and RhoA activities contribute to the dilated phenotype of Shp2-deficient hearts. Conclusions-Our results identify Shp2 as the first PTP with a critical role in adult cardiac function, indicate that in the absence of Shp2 cardiac hypertrophy does not occur in response to pressure overload, and demonstrate that the cardioprotective role of Shp2 is mediated via control of both the Erk/MAPK and RhoA signaling pathways. Key Words: cardiomyopathies Ⅲ heart diseases Ⅲ molecular biology Ⅲ myocardium Ⅲ myocytes Ⅲ signal transduction H eart failure is an emerging epidemic and a leading cause of death in the United States. 1 Delineating the signaling pathways that regulate normal survival, proliferation, and growth of cardiomyocytes and determining how these processes are deregulated are essential for us to understand the pathogenesis of cardiomyopathy and heart failure.
Clinical Perspective p 1435Cardiomyocytes respond to a variety of soluble endocrine, paracrine, and autocrine factors, as well as solid-state signals, which in turn stimulate an array of membrane-bound receptors. Soluble agonists include classic growth factors such as heregulin, epidermal growth factor (EGF), and insulin-like growth factor-1 (IGF-1), which signal via receptor tyrosine kinases (RTKs), and cytokines and ligands for G-proteincoupled receptors, 2 which signal, at least in part, via nonreceptor protein tyrosine kinases (PTKs). Solid-state signals (eg, ligands for integrins) also can activate nonreceptor PTKs. Upon receptor activation, PTK-associated receptors activate a number of downstream signaling cascades, including the Ras/extracellular signal-regulated kinase (Erk) mitogen-activated protein kinase (MAPK) pathway, other MAPKs (eg, Received May 11, 2007; accepted January 2, 2008. Although many cardiomyocyte signaling pathways involve PTKs, the role of specific protein tyrosine phosphatases (PTPs) in normal cardiac development and disease remains largely obscure. Shp2, a nonreceptor...